Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer.

Shannon McLaughlinErika NakajimaYael BarJennifer A HutchinsonJennifer ShinBeverly MoySteven J IsakoffAditya BardiaIrene KuterLaura M Spring

Published in: Therapeutic advances in medical oncology (2023)

Trastuzumab in combination with vinorelbine in the adjuvant, early-stage setting for low-risk HER2+ BC demonstrated clinical efficacy and appeared to be well tolerated. TV warrants further evaluation as an alternative regimen to TH for patients with early-stage HER2+ BC.

Keyphrases

early stage
sentinel lymph node
epidermal growth factor receptor
metastatic breast cancer
phase ii study
squamous cell carcinoma
radiation therapy
young adults
locally advanced
clinical evaluation